Company / Current Liabilities
Xeris Biopharma Holdings, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$109.6M
FY2025
5-year range
$73.6M / $109.6M
FY2021-FY2025
Trend
+9.1%
vs FY2024
Sector context
#90 of 213
Health Care
What the data says
At $110M, Xeris Biopharma Holdings, Inc.'s current liabilities ranks #124 of 213 in the Health Care sector. Current Liabilities has increased for 3 consecutive years, from $74M in FY2022 to $110M in FY2025.
Based on SEC 10-K filings.
$110M in FY2025 with a 5-year CAGR of +31.2%.
Increased from $95M to $110M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +14.2%
- 5-Year CAGR
- +31.2%
- 10-Year CAGR
- -
Sector benchmark
#124 of 213 in Health CareTop 58% of 213This company $109.6M Sector average $1.6B
▼
-93.1% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +31.2%, indicating consistent growth.
- In FY2025, current liabilities increased 9.1% year-over-year.
- Ranks #90 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $109.6M | +9.1% |
| FY2024 | $100.4M | +5.5% |
| FY2023 | $95.2M | +29.3% |
| FY2022 | $73.6M | -6.9% |
| FY2021 | $79.0M | +180.2% |
| FY2020 | $28.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026